GT201000032A - Derivados de indol-2-ona disustituidos en 3, su preparacion y su aplicacion terapeutica - Google Patents

Derivados de indol-2-ona disustituidos en 3, su preparacion y su aplicacion terapeutica

Info

Publication number
GT201000032A
GT201000032A GT201000032A GT201000032A GT201000032A GT 201000032 A GT201000032 A GT 201000032A GT 201000032 A GT201000032 A GT 201000032A GT 201000032 A GT201000032 A GT 201000032A GT 201000032 A GT201000032 A GT 201000032A
Authority
GT
Guatemala
Prior art keywords
derivatives
disstituted
indol
preparation
ona
Prior art date
Application number
GT201000032A
Other languages
English (en)
Inventor
Marco Baroni
Letizia Puleo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000032A publication Critical patent/GT201000032A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA YA QUE DICHOS DERIVADOS PUEDEN ACTUAR COMO ANTAGONISTAS DEL RECEPTOR DE LA GRELINA QUE ES UNA HORMONA PEPTÍDICA DE 28 AMINOÁCIDOS PRODUCIDA PRINCIPALMENTE EN EL ESTÓMAGO POR UN PROCESO POSTERIOR A LA TRADUCCIÓN DESPUÉS DE LA ESCISIÓN DE LA PRE-PRO-GRELINA POR LO QUE LA PRESENTE INVENCIÓN ES DE UTILIDAD CONTRA CUADROS DE OBESIDAD.
GT201000032A 2007-08-16 2010-02-10 Derivados de indol-2-ona disustituidos en 3, su preparacion y su aplicacion terapeutica GT201000032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0705858A FR2920023B1 (fr) 2007-08-16 2007-08-16 Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
GT201000032A true GT201000032A (es) 2012-03-12

Family

ID=39197313

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000032A GT201000032A (es) 2007-08-16 2010-02-10 Derivados de indol-2-ona disustituidos en 3, su preparacion y su aplicacion terapeutica

Country Status (42)

Country Link
US (2) US20100210662A1 (es)
EP (1) EP2188253B8 (es)
JP (1) JP5685440B2 (es)
KR (1) KR20100051812A (es)
CN (1) CN103443076B (es)
AR (1) AR067937A1 (es)
AT (1) ATE548349T1 (es)
AU (1) AU2008320718B2 (es)
BR (1) BRPI0815171A2 (es)
CA (1) CA2696237C (es)
CO (1) CO6251363A2 (es)
CR (1) CR11273A (es)
CY (1) CY1112809T1 (es)
DK (1) DK2188253T3 (es)
DO (1) DOP2010000050A (es)
EA (1) EA019486B1 (es)
EC (1) ECSP109961A (es)
ES (1) ES2384080T3 (es)
FR (1) FR2920023B1 (es)
GT (1) GT201000032A (es)
HN (1) HN2010000330A (es)
HR (1) HRP20120466T1 (es)
IL (1) IL203956A (es)
JO (1) JO2749B1 (es)
MA (1) MA31742B1 (es)
ME (1) ME00979B (es)
MX (1) MX2010001851A (es)
MY (1) MY149649A (es)
NI (1) NI201000023A (es)
NZ (1) NZ583317A (es)
PA (1) PA8793101A1 (es)
PE (1) PE20090988A1 (es)
PL (1) PL2188253T3 (es)
PT (1) PT2188253E (es)
RS (1) RS52321B (es)
SI (1) SI2188253T1 (es)
TN (1) TN2010000025A1 (es)
TW (1) TWI432423B (es)
UA (1) UA101162C2 (es)
UY (1) UY31297A1 (es)
WO (1) WO2009056707A2 (es)
ZA (1) ZA201001085B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
FR2941947B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN108658836B (zh) * 2018-05-15 2021-04-20 宁波大学 一种3-取代-3-叠氮基吲哚-2-酮类化合物的制备方法
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
US6576656B1 (en) * 1998-08-20 2003-06-10 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivative
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
WO2005035498A1 (ja) * 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 含窒素二環性化合物の摂食調節剤としての用途

Also Published As

Publication number Publication date
AU2008320718B2 (en) 2013-09-19
CN103443076B (zh) 2016-06-22
JO2749B1 (en) 2014-03-15
FR2920023B1 (fr) 2013-02-08
HRP20120466T1 (hr) 2012-07-31
WO2009056707A2 (fr) 2009-05-07
AR067937A1 (es) 2009-10-28
JP2010536736A (ja) 2010-12-02
MY149649A (en) 2013-09-30
EP2188253B8 (fr) 2012-04-11
MX2010001851A (es) 2010-03-11
WO2009056707A3 (fr) 2009-10-01
TWI432423B (zh) 2014-04-01
RS52321B (en) 2012-12-31
TW200914438A (en) 2009-04-01
US8202871B2 (en) 2012-06-19
CR11273A (es) 2010-07-16
UY31297A1 (es) 2009-03-31
US20100210662A1 (en) 2010-08-19
DOP2010000050A (es) 2010-04-15
ECSP109961A (es) 2010-03-31
ATE548349T1 (de) 2012-03-15
SI2188253T1 (sl) 2012-09-28
US20110118280A1 (en) 2011-05-19
ZA201001085B (en) 2011-04-28
WO2009056707A8 (fr) 2010-03-18
MA31742B1 (fr) 2010-10-01
JP5685440B2 (ja) 2015-03-18
PE20090988A1 (es) 2009-08-14
PT2188253E (pt) 2012-05-11
EP2188253A2 (fr) 2010-05-26
DK2188253T3 (da) 2012-07-02
TN2010000025A1 (fr) 2011-09-26
AU2008320718A1 (en) 2009-05-07
FR2920023A1 (fr) 2009-02-20
CY1112809T1 (el) 2016-02-10
PA8793101A1 (es) 2009-01-23
EA201070281A1 (ru) 2010-08-30
ME00979B (me) 2012-06-20
EA019486B1 (ru) 2014-04-30
KR20100051812A (ko) 2010-05-18
NI201000023A (es) 2010-03-11
CA2696237C (fr) 2016-07-05
PL2188253T3 (pl) 2012-08-31
CA2696237A1 (fr) 2009-05-07
BRPI0815171A2 (pt) 2015-03-31
CN103443076A (zh) 2013-12-11
ES2384080T3 (es) 2012-06-29
CO6251363A2 (es) 2011-02-21
EP2188253B1 (fr) 2012-03-07
NZ583317A (en) 2011-11-25
UA101162C2 (ru) 2013-03-11
IL203956A (en) 2014-06-30
HN2010000330A (es) 2012-03-19

Similar Documents

Publication Publication Date Title
GT201000032A (es) Derivados de indol-2-ona disustituidos en 3, su preparacion y su aplicacion terapeutica
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
TR201905586T4 (tr) Amorf dapagli̇flozi̇n i̇çeren formülasyonlar
EA200901339A1 (ru) Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
PH12014500922A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
MX2012008603A (es) Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
BR112012006346A2 (pt) agonista de receptor de acetilcolina, composto, composição farmacêutica, combinação e uso de ativadores de receptor de acetilcolina nicotínico alfa 7
AR071968A1 (es) Uso de un oligosacarido en el tratamiento de la inflamacion intestinal
MX2011009847A (es) Agentes antihelminticos y su uso.
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
DOP2011000354A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
CO6541545A2 (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
GT201200038A (es) Composicion para tratar la fibrosis quistica
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе